Get the Stockscreener App
4.05
0.49%
-0.02
Pre-market:
4.03
-0.02
-0.49%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $4.05, with a volume of 2.41M.
It is down -0.49% in the last 24 hours and up +7.43% over the past month.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$4.07
Open:
$4.25
24h Volume:
2.41M
Relative Volume:
0.88
Market Cap:
$357.44M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-2.4695
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
+2.53%
1M Performance:
+7.43%
6M Performance:
-22.86%
1Y Performance:
-39.91%
1-Day Range:
$3.99
$4.25
1-Week Range:
$3.93
$4.25
52-Week Range:
$2.90
$11.16
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
4.05 | 359.21M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Nov-12-24 | Initiated | UBS | Buy |
| Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-24-24 | Initiated | Goldman | Neutral |
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
Altimmune Inc. stock chart pattern explainedQuarterly Trade Review & Consistent Income Trade Ideas - newser.com
How strong is Altimmune Inc. stock revenue growthGlobal Markets & Weekly Momentum Stock Picks - newser.com
Using AI based signals to follow Altimmune Inc.July 2025 Momentum & Safe Investment Capital Preservation Plans - newser.com
Why Altimmune Inc. stock is a value investor pickGap Down & Long-Term Safe Investment Plans - newser.com
Altimmune, Inc. (NASDAQ:ALT) Receives Average Rating of "Hold" from Brokerages - MarketBeat
How Altimmune Inc. stock performs during Fed tightening cyclesMarket Risk Analysis & Free Low Drawdown Momentum Trade Ideas - newser.com
Technical analysis overview for Altimmune Inc. stockEarnings Trend Report & Precise Trade Entry Recommendations - newser.com
Altimmune (ALT) to Release Quarterly Earnings on Thursday - MarketBeat
Tools to monitor Altimmune Inc. recovery probability2025 Trade Ideas & Weekly Top Performers Watchlists - newser.com
Automated trading signals detected on Altimmune Inc.2025 Volume Leaders & Safe Capital Growth Trade Ideas - newser.com
Moody Aldrich Partners LLC Invests $610,000 in Altimmune, Inc. $ALT - MarketBeat
Can technical indicators confirm Altimmune Inc.’s reversalMarket Risk Report & Weekly High Return Stock Opportunities - newser.com
How to use Fibonacci retracement on Altimmune Inc.Weekly Stock Report & Consistent Profit Trade Alerts - newser.com
Biodefense Market to Attain USD 32.87 Billion by 2034, Driven by Biotech Advancements and Government Funding - GlobeNewswire Inc.
Forecasting Altimmune Inc. price range with options dataFed Meeting & Risk Managed Investment Entry Signals - newser.com
How to forecast Altimmune Inc. trends using time seriesWatch List & Free Risk Controlled Daily Trade Plans - newser.com
What technical charts say about Altimmune Inc. stockQuarterly Earnings Report & Reliable Price Breakout Signals - newser.com
What MACD and RSI say about Altimmune Inc.2025 Market Trends & Detailed Earnings Play Strategies - newser.com
Using fundamentals and technicals on Altimmune Inc.Risk Management & Community Consensus Stock Picks - newser.com
Should you wait for a breakout in Altimmune Inc.2025 Sector Review & Technical Analysis for Trade Confirmation - newser.com
Can momentum traders help lift Altimmune Inc.Quarterly Earnings Report & Consistent Profit Trading Strategies - newser.com
Altimmune: Competitor Buyouts Plus Regulatory And Clinical Progress (NASDAQ:ALT) - Seeking Alpha
Does Altimmune Inc. show high probability of reboundJuly 2025 Fed Impact & High Yield Equity Trading Tips - newser.com
Altimmune (Nasdaq: ALT) schedules Nov 6 results call at 8:30 a.m. ET with business update - Stock Titan
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Altimmune Inc Stock (ALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):